Sidra Ellis

578 total citations
5 papers, 10 citations indexed

About

Sidra Ellis is a scholar working on Hematology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Sidra Ellis has authored 5 papers receiving a total of 10 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Hematology, 4 papers in Molecular Biology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Sidra Ellis's work include Multiple Myeloma Research and Treatments (5 papers), Protein Degradation and Inhibitors (3 papers) and Cancer Mechanisms and Therapy (3 papers). Sidra Ellis is often cited by papers focused on Multiple Myeloma Research and Treatments (5 papers), Protein Degradation and Inhibitors (3 papers) and Cancer Mechanisms and Therapy (3 papers). Sidra Ellis collaborates with scholars based in United Kingdom. Sidra Ellis's co-authors include Martin Kaiser, Amy L. Sherborne, Gordon Cook, Julia Brown, David C. Johnson, Mamta Garg, Suzana S. Couto, Mark T. Drayson, Johann S. de Bono and Amy Price and has published in prestigious journals such as Blood.

In The Last Decade

Sidra Ellis

5 papers receiving 10 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sidra Ellis United Kingdom	3	10	9	5	2	2	5	10
Cody J. Boehner United States	2	9 0.9×	10 1.1×	4 0.8×	2 1.0×		4	10
Joan Bladé Creixenti Spain	3	12 1.2×	13 1.4×	5 1.0×	3 1.5×	1 0.5×	4	14
Elvira Umyarova United States	3	6 0.6×	8 0.9×	6 1.2×	2 1.0×	4 2.0×	13	17
Stojan Zavisic United States	3	7 0.7×	8 0.9×	5 1.0×	1 0.5×		7	11
Karine Celli Lebras France	2	11 1.1×	15 1.7×	4 0.8×	3 1.5×		2	18
August Williams United States	2	11 1.1×	6 0.7×	5 1.0×		1 0.5×	3	17
Vanessa Houck United Kingdom	3	6 0.6×	8 0.9×	6 1.2×			3	8
Amarendra Kumar Neppalli United States	3	5 0.5×	6 0.7×	6 1.2×	4 2.0×	2 1.0×	6	11
Alexandra Leutbecher Germany	2	7 0.7×	10 1.1×	8 1.6×	1 0.5×		3	29
Jayant Kumar United States	2	11 1.1×	7 0.8×	7 1.4×	1 0.5×	1 0.5×	3	17

Countries citing papers authored by Sidra Ellis

Since Specialization

Citations

This map shows the geographic impact of Sidra Ellis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sidra Ellis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sidra Ellis more than expected).

Fields of papers citing papers by Sidra Ellis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sidra Ellis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sidra Ellis. The network helps show where Sidra Ellis may publish in the future.

Co-authorship network of co-authors of Sidra Ellis

This figure shows the co-authorship network connecting the top 25 collaborators of Sidra Ellis. A scholar is included among the top collaborators of Sidra Ellis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sidra Ellis. Sidra Ellis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Jenner, Matthew, Amy L. Sherborne, Andrew Hall, et al.. (2019). Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172). Blood. 134(Supplement_1). 3162–3162. 1 indexed citations

2.

Hall, Andrew, Amy L. Sherborne, Katrina Walker, et al.. (2019). Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial. Blood. 134(Supplement_1). 4327–4327. 4 indexed citations

3.

Hall, Andrew, Katrina Walker, Amy L. Sherborne, et al.. (2018). Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial. Blood. 132(Supplement 1). 3274–3274. 2 indexed citations

4.

Sriskandarajah, Priya, Kevin Boyd, Wen Xu, et al.. (2018). Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS-mutant Multiple Myeloma. Blood. 132(Supplement 1). 3237–3237. 1 indexed citations

5.

Sherborne, Amy L., Vallari Shah, Sidra Ellis, et al.. (2017). Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial. Blood. 130. 1767–1767. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact